MCID: HMT002
MIFTS: 64

Hematologic Cancer

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 39 12 56 15
Hematologic Neoplasm 12 30 6
Hematologic Malignancy 12 15
Hematologic Neoplasms 45 74
Hematopoietic and Lymphoid System Tumor 12
Malignant Hematopoietic Neoplasm 12
Hematologic Malignancies 56
Hematopoietic Neoplasms 74
Hematopoietic Neoplasm 12
Hematological Tumors 12
Hematopoietic Cancer 12
Hematopoietic Tumors 12
Blood Cancer 12
Liquid Tumor 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2531
MeSH 45 D019337
NCIt 51 C27134

Summaries for Hematologic Cancer

Disease Ontology : 12 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary : Hematologic Cancer, also known as hematologic neoplasm, is related to bone marrow cancer and myelodysplastic myeloproliferative cancer. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant 6), and among its related pathways/superpathways are TGF-Beta Pathway and Cytokine Signaling in Immune system. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 32.7 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
2 myelodysplastic myeloproliferative cancer 32.6 ABL1 CSF2 JAK2
3 myeloproliferative neoplasm 32.4 ABL1 JAK2 KIT MPL
4 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 32.2 ETV6 FLT3 KIT KMT2A RUNX1
5 8p11 myeloproliferative syndrome 32.1 FLT3 KIT RUNX1
6 lymphoma, non-hodgkin, familial 32.0 CSF2 IL2 IL3 JAK2
7 myelodysplastic syndrome 31.3 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
8 myeloma, multiple 31.3 CSF2 IL2 JAK2 KIT PVT1
9 aplastic anemia 31.3 CSF2 FLT3 IL2 IL3 MPL
10 acute promyelocytic leukemia 31.2 FLT3 IL3 PVT1 RUNX1 WT1
11 acute leukemia 31.1 ETV6 FLT3 IL3 JAK2 KIT KMT2A
12 leukemia, chronic myeloid 31.1 ABL1 CBL CSF2 ETV6 FLT3 IL3
13 leukemia 31.0 ABL1 CSF2 ETV6 FLT3 JAK2 KIT
14 childhood leukemia 30.9 ABL1 ETV6 KMT2A RUNX1
15 myeloid sarcoma 30.9 FLT3 KIT KMT2A
16 polycythemia vera 30.8 ABL1 IL3 JAK2 KIT MPL
17 polycythemia 30.8 IL3 JAK2 MPL
18 leukemia, acute myeloid 30.7 ABL1 CCDC26 CSF2 ETV6 FLT3 IL2
19 myeloid leukemia 30.7 ABL1 CSF2 ETV6 FLT3 IL3 JAK2
20 pancytopenia 30.7 CSF2 IL3 MPL
21 leukemia, acute lymphoblastic 30.6 ABL1 ETV6 FLT3 KMT2A RUNX1
22 acute lymphocytic leukemia 30.6 CSF2 ETV6 IL2 RUNX1 XIST
23 myelofibrosis 30.6 FLT3 IL3 JAK2 KIT MPL
24 lymphocytic leukemia 30.6 ETV6 IL2 KMT2A RUNX1
25 diphtheria 30.6 CSF2 IL2 IL3
26 refractory anemia 30.5 IL3 JAK2 MPL RUNX1
27 essential thrombocythemia 30.5 ABL1 IL3 JAK2 MPL
28 retinitis pigmentosa and erythrocytic microcytosis 30.3 IL3 JAK2
29 central nervous system hematologic cancer 12.4
30 refractory hematologic cancer 12.4
31 myeloproliferative/lymphoproliferative neoplasms, familial 11.8
32 fusariosis 11.4
33 platelet disorder, familial, with associated myeloid malignancy 11.3
34 mismatch repair cancer syndrome 11.3
35 ras-associated autoimmune leukoproliferative disorder 11.2
36 systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease 11.2
37 medulloblastoma 11.0
38 anemia, sideroblastic, 1 11.0
39 surfactant metabolism dysfunction, pulmonary, 4 11.0
40 thrombocytopenia 5 11.0
41 mikulicz disease 11.0
42 scleredema adultorum 11.0
43 sideroblastic anemia 11.0
44 paroxysmal cold hemoglobinuria 11.0
45 pulmonary alveolar proteinosis, acquired 11.0
46 lymphoma 11.0
47 central nervous system leukemia 11.0
48 central nervous system lymphoma 11.0
49 mast cell neoplasm 11.0
50 histiocytic and dendritic cell cancer 11.0

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.1 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.1 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.1 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 ABL1 CBL CSF2 ENG ETV6 FLT3
2 cellular MP:0005384 10.37 ABL1 CBL CSF2 ETV6 FLT3 IL2
3 hematopoietic system MP:0005397 10.37 ABL1 CBL CSF2 ENG ETV6 FLT3
4 homeostasis/metabolism MP:0005376 10.32 ABL1 CBL CSF2 ENG ETV6 FLT3
5 cardiovascular system MP:0005385 10.31 ABL1 CBL CSF2 ENG ETV6 IL2
6 immune system MP:0005387 10.3 ABL1 CBL CSF2 ETV6 FLT3 IL2
7 embryo MP:0005380 10.28 ABL1 CSF2 ENG ETV6 JAK2 KIT
8 endocrine/exocrine gland MP:0005379 10.26 ABL1 CBL CSF2 ETV6 FLT3 IL2
9 mortality/aging MP:0010768 10.24 ABL1 CBL CSF2 ENG ETV6 FLT3
10 craniofacial MP:0005382 10.09 ABL1 CBL CSF2 ENG KIT KMT2A
11 integument MP:0010771 10.09 CBL CSF2 ENG ETV6 JAK2 KIT
12 liver/biliary system MP:0005370 10.06 ABL1 CBL IL2 JAK2 KIT KMT2A
13 neoplasm MP:0002006 10.02 CSF2 ETV6 FLT3 IL2 JAK2 KIT
14 normal MP:0002873 9.81 ABL1 ENG ETV6 JAK2 KIT KMT2A
15 no phenotypic analysis MP:0003012 9.8 ETV6 FLT3 IL2 KIT KMT2A RUNX1
16 respiratory system MP:0005388 9.61 ABL1 CBL CSF2 ENG IL2 KIT
17 skeleton MP:0005390 9.28 ABL1 CBL CSF2 FLT3 JAK2 KIT

Drugs & Therapeutics for Hematologic Cancer

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 569)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
6
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
7
Protein C Approved Phase 4,Phase 2
8
Pegaspargase Approved, Investigational Phase 4,Phase 1,Phase 2 130167-69-0
9
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
10
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 179324-69-7 387447 93860
11
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1 191732-72-6 216326
12
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
13
Caspofungin Approved Phase 4,Phase 3,Phase 2 179463-17-3, 162808-62-0 2826718 468682
14
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1 946414-94-4
15
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 477202-00-9
16 Daratumumab Approved Phase 4,Phase 3,Phase 2 945721-28-8
17
Ixazomib Approved, Investigational Phase 4,Phase 2 1072833-77-2
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Ofloxacin Approved Phase 4 82419-36-1 4583
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
30 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
37 Drotrecogin alfa activated Phase 4
38 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 220127-57-1 123596
40
asparaginase Phase 4,Phase 1,Phase 2
41 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46
Hydroxyitraconazole Phase 4
47 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 952)
# Name Status NCT ID Phase Drugs
1 A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) Completed NCT02966457 Phase 4 Colistimethate Sodium
2 A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
4 Dose Individualization of Antineoplastic Drugs in Children Recruiting NCT03844360 Phase 4 Bortezomib;Eltrombopag;Imatinib;dasatinib;Pegaspargase
5 Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Recruiting NCT03023631 Phase 4
6 An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers Recruiting NCT02869789 Phase 4 Nivolumab in combination with Ipilimumab
7 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
8 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Terminated NCT02895529 Phase 4 Itraconazole;Caspofungin
9 SubCutaneous (SC) Versus Intravenous (IV) Granulocyte Colony Stimulating Factors (G-CSF) for the Treatment of Neutropenia in Hospitalized Haemato-oncological Patients Terminated NCT01222819 Phase 4 filgrastim
10 Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
11 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
12 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
13 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
14 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
15 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
16 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
17 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
18 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
19 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
20 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Completed NCT01767467 Phase 3 Placebo
21 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
22 Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Completed NCT00075816 Phase 3
23 Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Completed NCT02635984 Phase 3 Olanzapine;Placebo
24 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed NCT00406393 Phase 3 Tacrolimus;Methotrexate;Sirolimus
25 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients Completed NCT00824993 Phase 3 Ibandronate;Vitamin Supplements
26 Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy Completed NCT01435200 Phase 3 Intravenous iron
27 Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation Completed NCT01237639 Phase 3
28 A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. Completed NCT00300664 Phase 2, Phase 3 Human Growth hormone
29 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
30 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
31 INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant Completed NCT01602211 Phase 3
32 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed NCT00750737 Phase 3 Posaconazole;ABLC
33 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
34 A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients Completed NCT01769170 Phase 3 Brincidofovir (CMX001)
35 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
36 Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients Completed NCT01568866 Phase 3 Carfilzomib;Bortezomib;Dexamethasone
37 Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT02229539 Phase 3 doxepin hydrochloride oral solution;DLA (diphenhydramine, lidocaine and antacids) rinse
38 Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy Completed NCT02116530 Phase 3 Olanzapine;Chemotherapy (cisplatin or cyclophosphamide and doxorubicin);Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
39 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
40 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Completed NCT01598298 Phase 3 duloxetine hydrochloride
41 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed NCT01109004 Phase 3 Lenalidomide;lenalidomide, bortezomib and dexamethasone;Lenalidomide
42 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
43 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
44 PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00048230 Phase 3 bortezomib
45 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) Completed NCT01410227 Phase 3 Placebo
46 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
47 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. Completed NCT02292446 Phase 3 Ruxolitinib
48 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
49 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
50 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord�, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx�, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 23711284 21277377
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 30 HIST1H3B

Anatomical Context for Hematologic Cancer

MalaCards organs/tissues related to Hematologic Cancer:

42
Bone, Bone Marrow, T Cells, Breast, Myeloid, B Cells, Testes

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 58)
# Title Authors Year
1
Risk for depression and anxiety in long-term survivors of hematologic cancer. ( 30762398 )
2019
2
Frailty Prevalence and Characteristics in Older Adults with Hematologic Cancer: a Descriptive Study. ( 30599015 )
2019
3
High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles. ( 30693332 )
2019
4
Pre- and post-diagnosis physical activity, television viewing, and mortality among hematologic cancer survivors. ( 29385194 )
2018
5
Feasibility and preliminary efficacy of an exercise telephone counseling intervention for hematologic cancer survivors: a phase II randomized controlled trial. ( 29411314 )
2018
6
Factors influencing infection prevention self-care behaviors in patients with hematologic cancer after discharge. ( 30057076 )
2018
7
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. ( 30254093 )
2018
8
The Impact of Hematologic Cancer and Its Treatment on Physical Activity Level and Quality of Life Among Children in Mainland China: A Descriptive Study. ( 30433896 )
2018
9
Social Cognitive Effects and Mediators of a Pilot Telephone Counseling Intervention to Increase Aerobic Exercise in Hematologic Cancer Survivors. ( 30501541 )
2018
10
Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy. ( 30613077 )
2018
11
Practice-relevant demarcation of systemic mastocytosis associated with another hematologic neoplasm. ( 30156701 )
2018
12
Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000-2016): Uncommon, with improved survival but still deadly often. ( 28919347 )
2017
13
Psychological distress, chronic conditions and quality of life in elderly hematologic cancer patients: study protocol of a prospective study. ( 29070033 )
2017
14
Childhood hematologic cancer and residential proximity to oil and gas development. ( 28199334 )
2017
15
Body Image Discomfort of Adolescent and Young Adult Hematologic Cancer Survivors. ( 28112547 )
2017
16
Correlates of meeting the combined and independent aerobic and strength exercise guidelines in hematologic cancer survivors. ( 28351397 )
2017
17
Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. ( 28778967 )
2017
18
Living with hematologic cancer: Recommendations, solutions. ( 28696193 )
2017
19
Understanding strength exercise intentions and behavior in hematologic cancer survivors: an analysis of the intention-behavior gap. ( 27052642 )
2016
20
Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. ( 27400009 )
2016
21
Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? ( 27282880 )
2016
22
Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. ( 26763882 )
2016
23
Associations between dyadic coping and supportive care needs: findings from a study with hematologic cancer patients and their partners. ( 27987096 )
2016
24
Survivorship Care Plans and Treatment Summaries a8"in Adult Patients With Hematologic Cancer: a8"An Integrative Literature Review. ( 25901380 )
2015
25
Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. ( 26310541 )
2015
26
Cancer Care Burden among Primary Family Caregivers of Iranian Hematologic Cancer Patients. ( 26225701 )
2015
27
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B And Caspofungin for Primary Therapy of Invasive Aspergillosis Among High-Risk Hematologic Cancer Patients In Saudi Arabia. ( 26533739 )
2015
28
Hospitalization risk according to geriatric assessment and laboratory parameters in elderly hematologic cancer patients. ( 25684525 )
2015
29
Cost Analysis of Voriconazole Versus Liposomal Amphotericin B for Primary Therapy of Invasive Aspergillosis among High-Risk Hematologic Cancer Patients in Brazil. ( 26534377 )
2015
30
Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm. ( 26628205 )
2015
31
The falling incidence of hematologic cancer after heart transplantation. ( 25100534 )
2014
32
The microfluidic multitrap nanophysiometer for hematologic cancer cell characterization reveals temporal sensitivity of the calcein-AM efflux assay. ( 24873950 )
2014
33
Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. ( 24645687 )
2014
34
Anti-tumor activity and relative mechanism of ethanolic extract of Marsdenia tenacissima (Asclepiadaceae) against human hematologic neoplasm in vitro and in vivo. ( 24583069 )
2014
35
Internet-based program for coping with cancer: a randomized controlled trial with hematologic cancer patients. ( 22565413 )
2013
36
Confirmation of the reported association of clonal chromosomal mosaicism with an increased risk of incident hematologic cancer. ( 23533652 )
2013
37
Xist RNA is a potent suppressor of hematologic cancer in mice. ( 23415223 )
2013
38
Expression of ICOSLG on mouse hematologic neoplasm cell lines and their influence on cytotoxicity in allogeneic mixed lymphocyte reactions. ( 21958057 )
2012
39
Physical activity and hematologic cancer prevention. ( 21113763 )
2011
40
Improving access to information and support for patients with less common cancers: hematologic cancer patients' views about Web-based approaches. ( 22189354 )
2011
41
Evolving information priorities of hematologic cancer survivors, caregivers, and other relatives. ( 20119694 )
2010
42
Mesial temporal sclerosis as a complication of hematologic cancer. ( 19434437 )
2009
43
Managed care considerations: hematologic cancer as a chronic disease. ( 19119536 )
2008
44
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. ( 18344563 )
2008
45
Phase 3 trials suggest ways to improve current hematologic cancer therapies. ( 18252877 )
2008
46
Femoral resurfacing in young patients with hematologic cancer and osteonecrosis. ( 18679763 )
2008
47
Posaconazole prophylaxis in hematologic cancer. ( 17526089 )
2007
48
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. ( 17607669 )
2007
49
Posaconazole prophylaxis in hematologic cancer. ( 17526091 )
2007
50
Posaconazole prophylaxis in hematologic cancer. ( 17526090 )
2007

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

6 (show all 32)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
2 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh37 Chromosome 12, 12022535: 12022535
3 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
4 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh37 Chromosome 12, 12037475: 12037475
5 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902
6 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh38 Chromosome 12, 11885968: 11885968
7 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh37 Chromosome 11, 119148891: 119148891
8 CBL NM_005188.3(CBL): c.1111T> C (p.Tyr371His) single nucleotide variant Pathogenic rs267606706 GRCh38 Chromosome 11, 119278181: 119278181
9 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh37 Chromosome 4, 55599321: 55599321
10 KIT NM_000222.2(KIT): c.2447A> T (p.Asp816Val) single nucleotide variant Uncertain significance rs121913507 GRCh38 Chromosome 4, 54733155: 54733155
11 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
12 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
13 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
14 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic rs121913506 GRCh38 Chromosome 4, 54733154: 54733154
15 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
16 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh38 Chromosome 4, 54728055: 54728055
17 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh37 Chromosome 1, 43815009: 43815009
18 MPL NM_005373.2(MPL): c.1544G> T (p.Trp515Leu) single nucleotide variant Pathogenic rs121913615 GRCh38 Chromosome 1, 43349338: 43349338
19 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh37 Chromosome 11, 119148930: 119148930
20 CBL NM_005188.3(CBL): c.1150T> C (p.Cys384Arg) single nucleotide variant Pathogenic/Likely pathogenic rs387906664 GRCh38 Chromosome 11, 119278220: 119278220
21 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh37 Chromosome 5, 149441328: 149441328
22 CSF1R NM_005211.3(CSF1R): c.1711T> G (p.Tyr571Asp) single nucleotide variant Likely pathogenic rs1057519802 GRCh38 Chromosome 5, 150061765: 150061765
23 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
24 CSF1R NM_005211.3(CSF1R): c.2906A> T (p.Tyr969Phe) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
25 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh38 Chromosome 5, 150054082: 150054082
26 CSF1R NM_005211.3(CSF1R): c.2906A> G (p.Tyr969Cys) single nucleotide variant Likely pathogenic rs1801271 GRCh37 Chromosome 5, 149433645: 149433645
27 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh37 Chromosome 5, 149433646: 149433646
28 CSF1R NM_005211.3(CSF1R): c.2905T> C (p.Tyr969His) single nucleotide variant Likely pathogenic rs121913393 GRCh38 Chromosome 5, 150054083: 150054083
29 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh38 Chromosome 5, 150073481: 150073481
30 CSF1R NM_005211.3(CSF1R): c.902T> C (p.Leu301Ser) single nucleotide variant Likely pathogenic rs121913390 GRCh37 Chromosome 5, 149453044: 149453044
31 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh37 Chromosome 5, 149453043: 149453043
32 CSF1R NM_005211.3(CSF1R): c.903G> T (p.Leu301Phe) single nucleotide variant Likely pathogenic rs1057520014 GRCh38 Chromosome 5, 150073480: 150073480

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 CBL FLT3 HIST1H3B IL2 IL3 JAK2
2
Show member pathways
13.2 CBL CSF2 FLT3 HIST1H3B IL2 IL3
3
Show member pathways
13.19 ABL1 CSF2 HIST1H3B IL2 IL3 JAK2
4
Show member pathways
12.69 ABL1 CBL CSF2 FLT3 IL3 KIT
5 12.48 ABL1 CBL FLT3 IL2 IL3 JAK2
6
Show member pathways
12.4 CBL CSF2 IL2 IL3
7 12.32 CBL IL2 IL3 JAK2 KIT MPL
8
Show member pathways
12.28 CBL FLT3 IL2 IL3 KIT
9
Show member pathways
12.21 CBL FLT3 IL3 JAK2
10
Show member pathways
12.16 ABL1 CSF2 IL2 IL3 JAK2 MPL
11
Show member pathways
12.04 CBL IL3 JAK2 KIT
12
Show member pathways
12.01 CSF2 IL2 IL3 JAK2
13 11.94 ABL1 CBL FLT3 JAK2 KIT
14 11.76 ABL1 IL2 IL3 JAK2
15 11.76 CSF2 FLT3 IL3 KIT
16 11.68 IL2 KIT RUNX1
17
Show member pathways
11.65 CSF2 IL2 IL3
18 11.63 CSF2 FLT3 IL2 KIT
19 11.56 CSF2 ENG FLT3 IL2 IL3 KIT
20 11.55 ABL1 IL2 WT1
21 11.49 CSF2 ETV6 FLT3 HIST1H3B IL3 KMT2A
22 11.4 CSF2 IL3 RUNX1
23 11.2 ABL1 HIST1H3B JAK2
24 11.13 CSF2 IL2 IL3
25 10.92 CSF2 FLT3 IL2 IL3 KIT
26 10.83 CBL KIT

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.87 CSF2 FLT3 IL2 IL3 JAK2 KIT
2 male gonad development GO:0008584 9.8 CBL KIT WT1
3 negative regulation of apoptotic process GO:0043066 9.79 CBL IL2 WT1
4 protein autophosphorylation GO:0046777 9.76 ABL1 FLT3 JAK2 KIT
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.75 ABL1 IL3 JAK2
6 MAPK cascade GO:0000165 9.73 CSF2 FLT3 IL2 IL3 JAK2 KIT
7 hemopoiesis GO:0030097 9.72 FLT3 KIT RUNX1
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 CBL FLT3 JAK2 KIT
9 regulation of megakaryocyte differentiation GO:0045652 9.7 HIST1H3B KMT2A RUNX1
10 peptidyl-tyrosine phosphorylation GO:0018108 9.63 ABL1 CSF2 FLT3 IL3 JAK2 KIT
11 regulation of regulatory T cell differentiation GO:0045589 9.62 IL2 RUNX1
12 interleukin-6-mediated signaling pathway GO:0070102 9.61 CBL JAK2
13 regulation of hematopoietic stem cell differentiation GO:1902036 9.61 ABL1 KMT2A RUNX1
14 negative regulation of cell-cell adhesion GO:0022408 9.6 ABL1 JAK2
15 mast cell degranulation GO:0043303 9.59 CBL KIT
16 hematopoietic stem cell proliferation GO:0071425 9.58 ETV6 RUNX1
17 dendritic cell differentiation GO:0097028 9.57 CSF2 FLT3
18 regulation of myeloid cell differentiation GO:0045637 9.56 CSF2 RUNX1
19 cytokine-mediated signaling pathway GO:0019221 9.56 CBL CSF2 FLT3 IL2 IL3 JAK2
20 negative regulation of heart contraction GO:0045822 9.54 IL2 JAK2
21 embryonic hemopoiesis GO:0035162 9.54 IL3 KIT KMT2A
22 positive regulation of vascular smooth muscle cell differentiation GO:1905065 9.51 ENG KIT
23 regulation of cytokine-mediated signaling pathway GO:0001959 9.49 IL3 RUNX1
24 myeloid progenitor cell differentiation GO:0002318 9.48 FLT3 KIT
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.43 ABL1 CSF2 FLT3 IL3 JAK2 KIT
2 peptide hormone receptor binding GO:0051428 9.26 JAK2 PTHLH
3 transmembrane signaling receptor activity GO:0004888 9.16 ENG MPL
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.1 CSF2 FLT3 IL2 IL3 JAK2 KIT

Sources for Hematologic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....